


Shifting (Mitigation of) Daratumumab in Myeloma plasma using modified anti-Daratumumab idiotype antibody in a serum immunofixation assay. *Samples:* All lanes contain Human IgG-Kappa plasma samples. Lanes 1-4 contain the one patient sample, Lanes 5-8 contain a different patient sample. Lanes 1 & 5 contain only the patient sample, Lanes 3, 4, 7 & 8 contain patient samples + daratumumab, and Lanes 4 & 8 also contain modified Anti-Daratumuab (A85-002A-modified). Row A samples were reacted with anti-human IgG antisera, Row B samples were reacted with anti-human Kappa light chain. Lane 2 & 6 are serum protein electrophoresis of the patient samples without daratumumab.



Inhibition of Daratumumab-HRP binding to Recombinant CD38 by ELISA. *Samples:* Solid phase immobilized recombinant CD38 incubated with HRP conjugated Daratumumab (0.5 ug/ml) in the presence increasing concentrations of Goat anti-Daratumumab idiotypic antibody (A85-002A).